| Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. | |
| | |
MedLine Citation:
|
PMID: 20685551 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Preeclampsia is a common complication of pregnancy with potentially devastating consequences to both the mother and the baby.It is the leading cause of maternal deaths in developing countries. In developed countries it is the major cause of iatrogenic premature delivery and contributes significantly to increasing health care cost associated with prematurity. There is currently no known treatment for preeclampsia; ultimate treatment involves delivery of the placenta. Although there are several risk factors (such as multiple gestation or chronic hypertension), most patients present with no obvious risk factors. The molecular pathogenesis of preeclampsia is just now being elucidated. It has been proposed that abnormal placentation and an imbalance in angiogenic factors lead to the clinical findings and complications seen in preeclampsia. Preeclampsia is characterized by high levels of circulating antiangiogenic factors such as soluble fms-like tyrosine kinase-1 and soluble endoglin, which induce maternal endothelial dysfunction. These soluble factors are altered not only at the time of clinical disease but also several weeks before the onset of clinical signs and symptoms. Many methods of prediction and surveillance have been proposed to identify women who will develop preeclampsia, but studies have been inconclusive. With the recent discovery of the role of angiogenic factors in preeclampsia, novel methods of prediction and diagnosis are being developed to aid obstetricians and midwives in clinical practice. This article discusses the role of angiogenic factors in the pathogenesis, prediction, diagnosis, and possible treatment of preeclampsia. |
| | |
Authors:
|
Michelle Silasi; Bruce Cohen; S Ananth Karumanchi; Sarosh Rana |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Obstetrics and gynecology clinics of North America Volume: 37 ISSN: 1558-0474 ISO Abbreviation: Obstet. Gynecol. Clin. North Am. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-08-05 Completed Date: 2010-12-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8709551 Medline TA: Obstet Gynecol Clin North Am Country: United States |
Other Details:
|
Languages: eng Pagination: 239-53 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 Elsevier Inc. All rights reserved. |
Affiliation:
|
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Kirstein 3182, Boston, MA 02215, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiogenic Proteins*
/
physiology Female Fetal Diseases / etiology Humans Neovascularization, Physiologic Placenta / blood supply Placenta Diseases / physiopathology Placentation* Pre-Eclampsia / etiology*, physiopathology, therapy Pregnancy Protein-Tyrosine Kinases Vascular Endothelial Growth Factor A |
| Grant Support | |
ID/Acronym/Agency:
|
5K12 HD001255-08/HD/NICHD NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenic Proteins; 0/Vascular Endothelial Growth Factor A; EC 2.7.10.1/Protein-Tyrosine Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sickle cell disease in pregnancy.
Next Document: Update on gestational diabetes.